FIBROGEN INC - COMMON

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

20 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

14 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

04 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

20 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2021 Financial Results

09 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

02 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2021 Financial Results

26 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

25 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

25 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

19 Aug 2021 19:35:00 By Nasdaq GlobeNewswire

FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

16 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

11 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2021 Financial Results

09 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2021 Financial Results

29 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

19 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

15 Jul 2021 18:26:31 By Nasdaq GlobeNewswire

FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

12 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

25 Jun 2021 09:15:00 By Nasdaq GlobeNewswire